UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 193

Sortiert nach

The Cannabis Act: implications for human participant research with cannabis

Journal of psychiatry & neuroscience, 2024-05, Vol.49 (3), p.E212-E217

2024

Volltextzugriff (PDF)

Preclinical anticancer activity of the potent, oral Src inhibitor AZD0530

Molecular oncology, 2009-06, Vol.3 (3), p.248-261

2009

Volltextzugriff (PDF)

Gene Array and Fluorescence In situ Hybridization Biomarkers of Activity of Saracatinib (AZD0530), a Src Inhibitor, in a Preclinical Model of Colorectal Cancer

Clinical cancer research, 2010-08, Vol.16 (16), p.4165-4177

2010

Volltextzugriff (PDF)

Nonclinical Selection Criteria for Maximizing Yield of Nucleic Acid Amplification Tests in Tuberculosis Diagnosis

Journal of Clinical Microbiology, 2012-08, Vol.50 (8), p.2592-2595

2012

Volltextzugriff (PDF)

Abstract 1019: P300/CBP inhibitor CCS1477 targets 22Rv1 prostate tumor AR and c-myc gene expression in vivo

Cancer research (Chicago, Ill.), 2019-07, Vol.79 (13_Supplement), p.1019-1019

2019

Volltextzugriff (PDF)

Abstract 3826: CCS1477, a potent and selective p300/CBP bromodomain inhibitor, is targeted & differentiated from BET inhibitors in prostate cancer cell lines in vitro

Cancer research (Chicago, Ill.), 2019-07, Vol.79 (13_Supplement), p.3826-3826

2019

Volltextzugriff (PDF)

Androgen Receptor Inhibitor Enhances the Antitumor Effect of PARP Inhibitor in Breast Cancer Cells by Modulating DNA Damage Response

Molecular cancer therapeutics, 2018-12, Vol.17 (12), p.2507-2518

2018

Volltextzugriff (PDF)

Abstract 3957: Analyzing the effects of radiotherapy on the metastatic phenotype: a role for combined therapeutic approaches incorporating Src and PI3K targeting

Cancer research (Chicago, Ill.), 2014-10, Vol.74 (19_Supplement), p.3957-3957

2014

Volltextzugriff (PDF)

Estimated costs of false laboratory diagnoses of tuberculosis in three patients

Emerging infectious diseases, 2002-11, Vol.8 (11), p.1264-1270

2002

Volltextzugriff (PDF)

A retrospective analysis of RET translocation, gene copy number gain and expression in NSCLC patients treated with vandetanib in four randomized Phase III studies

BMC cancer, 2015-03, Vol.15 (1), p.171, Article 171

2015

Volltextzugriff (PDF)

Regional copy number-independent deregulation of transcription in cancer

Nature genetics, 2006-12, Vol.38 (12), p.1386-1396

2006

Volltextzugriff (PDF)

Antitumor activity of saracatinib (AZD0530), a c-Src/Abl kinase inhibitor, alone or in combination with chemotherapeutic agents in gastric cancer

Molecular cancer therapeutics, 2013-01, Vol.12 (1), p.16-26

2013

Volltextzugriff (PDF)

Inhibition of Src Impairs the Growth of Met-Addicted Gastric Tumors

Clinical cancer research, 2010-08, Vol.16 (15), p.3933-3943

2010

Volltextzugriff (PDF)

Abstract LB-110: Expression of multiple androgen receptor splice variants in late stage prostate cancer

Cancer research (Chicago, Ill.), 2015-08, Vol.75 (15_Supplement), p.LB-110-LB-110

2015

Volltextzugriff (PDF)

Src activity is modulated by oxaliplatin and correlates with outcomes after hepatectomy for metastatic colorectal cancer

BMC cancer, 2014-09, Vol.14 (1), p.660-660, Article 660

2014

Volltextzugriff (PDF)

Abstract 2250: Combination of PARP inhibitor, Olaparib with pathway-targeted drug, vandetanib (Caprelsa™) in TNBC: A proof of principle study to determine the role of PI3K-AKT-mTOR or RAS-MAPK pathways in targeted drug-response

Cancer research (Chicago, Ill.), 2012-04, Vol.72 (8_Supplement), p.2250-2250

2012

Volltextzugriff (PDF)

Abstract 738: Increased Ret signalling and impact of vandetanib in acquired tamoxifen resistant breast cancer

Cancer research (Chicago, Ill.), 2014-10, Vol.74 (19_Supplement), p.738-738

2014

Volltextzugriff (PDF)

A pharmacokinetically (PK) and pharmacodynamically (PD) driven phase I trial of the pan-AKT inhibitor AZD5363 with expansion cohorts in PIK3CA mutant breast and gynecological cancers

Journal of clinical oncology, 2015-05, Vol.33 (15_suppl), p.2500-2500

2015

Volltextzugriff (PDF)

Abstract 558: Targeting tumour heparanase activity using fully human monoclonal antibodies

Cancer research (Chicago, Ill.), 2011-04, Vol.71 (8_Supplement), p.558-558

2011

Volltextzugriff (PDF)

Tumour invasion and metastasis: challenges facing drug discovery

Current opinion in pharmacology, 2005-08, Vol.5 (4), p.374-381

2005

Volltextzugriff (PDF)

Relationship of Src activity and prior oxaliplatin on outcomes after hepatectomy for metastatic colorectal cancer

Journal of clinical oncology, 2012-05, Vol.30 (15_suppl), p.3561-3561

2012

Volltextzugriff (PDF)

Retrospective evaluation of RET biomarker status and outcome to vandetanib in four phase III randomized NSCLC trials

Journal of clinical oncology, 2013-05, Vol.31 (15_suppl), p.8045-8045

2013

Volltextzugriff (PDF)

Pharmacodynamic activity of the AKT inhibitor AZD5363 in patients with advanced solid tumors

Journal of clinical oncology, 2014-05, Vol.32 (15_suppl), p.2541-2541

2014

Volltextzugriff (PDF)

Abstract LB-66: Results of two phase I multicenter trials of AZD5363, an inhibitor of AKT1, 2 and 3: Biomarker and early clinical evaluation in Western and Japanese patients with advanced solid tumors

Cancer research (Chicago, Ill.), 2013-04, Vol.73 (8_Supplement), p.LB-66-LB-66

2013

Volltextzugriff (PDF)

1 – 25 von 193

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(166)
Mit Volltextzugriff
(169)

Publikationsform

3 weitere anzeigen...

Weniger anzeigen...

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(105)
Life Sciences & Biomedicine
(84)
Humans
(76)
Female
(38)
Male
(35)
Cardiovascular System & Cardiology
(24)
Cardiac & Cardiovascular Systems
(23)
Adult
(20)
Middle Aged
(20)
Animals
(18)
Hiv
(18)
Aged
(17)
Biological And Medical Sciences
(17)
Infectious Diseases
(16)
Treatment Outcome
(14)
Mortality
(13)
Oncology
(13)
Patients
(13)
Time Factors
(13)
Science & Technology - Other Topics
(12)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

The Cannabis Act: implications for human participant research with cannabis

A Phase I Open-Label Study to Identify a Dosing Regimen of the Pan-AKT Inhibitor AZD5363 for Evaluation in Solid Tumors and in PIK3CA -Mutated Breast and Gynecologic Cancers

Preclinical anticancer activity of the potent, oral Src inhibitor AZD0530

Gene Array and Fluorescence In situ Hybridization Biomarkers of Activity of Saracatinib (AZD0530), a Src Inhibitor, in a Preclinical Model of Colorectal Cancer

Nonclinical Selection Criteria for Maximizing Yield of Nucleic Acid Amplification Tests in Tuberculosis Diagnosis

Abstract 1019: P300/CBP inhibitor CCS1477 targets 22Rv1 prostate tumor AR and c-myc gene expression in vivo

Abstract 3826: CCS1477, a potent and selective p300/CBP bromodomain inhibitor, is targeted & differentiated from BET inhibitors in prostate cancer cell lines in vitro

Androgen Receptor Inhibitor Enhances the Antitumor Effect of PARP Inhibitor in Breast Cancer Cells by Modulating DNA Damage Response

Abstract 3957: Analyzing the effects of radiotherapy on the metastatic phenotype: a role for combined therapeutic approaches incorporating Src and PI3K targeting

Estimated costs of false laboratory diagnoses of tuberculosis in three patients

A retrospective analysis of RET translocation, gene copy number gain and expression in NSCLC patients treated with vandetanib in four randomized Phase III studies

Regional copy number-independent deregulation of transcription in cancer

Antitumor activity of saracatinib (AZD0530), a c-Src/Abl kinase inhibitor, alone or in combination with chemotherapeutic agents in gastric cancer

Inhibition of Src Impairs the Growth of Met-Addicted Gastric Tumors

Abstract LB-110: Expression of multiple androgen receptor splice variants in late stage prostate cancer

Src activity is modulated by oxaliplatin and correlates with outcomes after hepatectomy for metastatic colorectal cancer

Abstract 2250: Combination of PARP inhibitor, Olaparib with pathway-targeted drug, vandetanib (Caprelsa™) in TNBC: A proof of principle study to determine the role of PI3K-AKT-mTOR or RAS-MAPK pathways in targeted drug-response

Abstract 738: Increased Ret signalling and impact of vandetanib in acquired tamoxifen resistant breast cancer

A pharmacokinetically (PK) and pharmacodynamically (PD) driven phase I trial of the pan-AKT inhibitor AZD5363 with expansion cohorts in PIK3CA mutant breast and gynecological cancers

Abstract 558: Targeting tumour heparanase activity using fully human monoclonal antibodies

Tumour invasion and metastasis: challenges facing drug discovery

Relationship of Src activity and prior oxaliplatin on outcomes after hepatectomy for metastatic colorectal cancer

Retrospective evaluation of RET biomarker status and outcome to vandetanib in four phase III randomized NSCLC trials

Pharmacodynamic activity of the AKT inhibitor AZD5363 in patients with advanced solid tumors

Abstract LB-66: Results of two phase I multicenter trials of AZD5363, an inhibitor of AKT1, 2 and 3: Biomarker and early clinical evaluation in Western and Japanese patients with advanced solid tumors

Suchergebnisse filtern